By Gro Grimnes
PhD-student at TREC
In a recently published study, we found that acute infection in hospitalized patients is a strong trigger for venous thromboembolism. The risk of venous thromboembolism increases even more if infection and immobilization co-exist.
By Nadia Arshad, PhD at TREC
Venous thrombosis (VTE) is a common term for blood clots in the deep veins of the body and/or in the lungs. Vitamin K antagonists (VKA) are within the group of blood-thinning medicines called anticoagulants, and are used to treat blood clots. A study accepted for publication in the Journal of Thrombosis and Hemostasis on 28th March 2016, discussed the risk of VTE recurrence (rVTE) during the first 2-months after stopping anticoagulants. Continue reading
By Ina I. Høiland, PhD student at TREC
Venous thromboembolism (VTE) is a common complication in cancer patients, and cancer patients are at increased risk for recurrent venous thromboembolism. Despite the well-established association between cancer and venous thromboembolism, there are few studies about the economic burden of venous thromboembolism in cancer patients. To asses, this a group at the Department of Health Sciences Research, Mayo Clinic, Rochester, USA recently conducted a population-based cohort study to estimate the medical costs associated with cancer associated VTE. Continue reading
av Olga Vikhammer Gran, stipendiat TREC
I de to siste tiårene har retningslinjene til American College of Chest Physicians (ACCP) vært hovedguiden for evidensbasert, anbefalt behandling av venøs blodpropp. Disse retningslinjene er rettet mot leger som behandler pasienter med dyp venetrombose eller lungeemboli. Den tiende utgaven av anbefalinger for behandling av venøs blodpropp ble utgitt av ACCP 8. Januar 2016. Den forrige (niende) utgaven ble utgitt i 2012. Retningslinjene er et 38-siders dokument som gir 30 individuelle anbefalinger og grad av evidens bak valgene. Continue reading
By Robin Liang, PhD in TREC
There is a continuous search for finding laboratory markers that are associated with an increased risk of venous thromboembolism (VTE). While the focus has been mainly on procoagulant pathways that form the clot, there have been relatively few studies that
examine fibrinolytic (clot-breaking) activity in relation to the risk of VTE. Continue reading
By Robin Liang, PhD in TREC
The ideal duration of anticoagulation following an unprovoked pulmonary embolism is controversial.
Studies have shown that after anticoagulant therapy is stopped after 3 or 6 months following an unprovoked venous thromboembolism (VTE), patients have a much higher risk than those VTE events provoked by known risk factors. Previous studies have shown that extended therapy reduces the risk in these high-risk patients, but whether this benefit is maintained in the long-term has not yet been investigated. Continue reading
